| Shawn Ulmen, CRNA | |
|
446 Bellevue Ave, Trenton, NJ 08618-4502 | |
| (609) 394-4221 | |
| (609) 394-4681 |
| Full Name | Shawn Ulmen |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 19 Years |
| Location | 446 Bellevue Ave, Trenton, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710934856 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | RN509865L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Jefferson Heath | Philadelphia, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Aria Health Physician Services | 3577467018 | 418 |
News Archive
Axial Exchange, Inc., a pioneer in using mobile applications to deepen the patient's role in improving outcomes, launched a new Spanish-language version of its mobile application, making the company's innovative patient engagement tools available to a greater population.
Princeton University researchers have observed a self-degradation response to the antidepressant Zoloft in yeast cells that could help provide new answers to lingering questions among scientists about how antidepressants work, as well as support the idea that depression is not solely linked to the neurotransmitter serotonin.
Sonomax Technologies Inc. is pleased to announce that it has signed its first licensing deal whereby its groundbreaking V4 technology has been licensed to Creare Inc. (Creare) for use in a Research and Development (R&D) project being executed on behalf of the United States Navy. If the synergy of Creare and Sonomax produces a product or technology that can be commercialized, then it is agreed that both parties will work together to explore opportunities to jointly license the combined technology.
In the first study of its kind, New England Research Institutes, Inc. (NERI) in collaboration with the Division of Cardiology, San Francisco General Hospital and the University of California, San Francisco tested whether erectile dysfunction (ED) can be used to reclassify patients according to their future risk of developing cardiovascular disease (CVD) beyond traditional risk factors (such as smoking, high blood pressure, high cholesterol, etc).
Among breast cancer patients, both chemotherapy and tamoxifen independently reduced the risk of developing a second cancer in the other breast, according to a study published online December 25 in the Journal of the National Cancer Institute.
› Verified 2 days ago
| Entity Name | Group Anesthesiologists' Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447285481 PECOS PAC ID: 4789588849 Enrollment ID: O20031121000076 |
News Archive
Axial Exchange, Inc., a pioneer in using mobile applications to deepen the patient's role in improving outcomes, launched a new Spanish-language version of its mobile application, making the company's innovative patient engagement tools available to a greater population.
Princeton University researchers have observed a self-degradation response to the antidepressant Zoloft in yeast cells that could help provide new answers to lingering questions among scientists about how antidepressants work, as well as support the idea that depression is not solely linked to the neurotransmitter serotonin.
Sonomax Technologies Inc. is pleased to announce that it has signed its first licensing deal whereby its groundbreaking V4 technology has been licensed to Creare Inc. (Creare) for use in a Research and Development (R&D) project being executed on behalf of the United States Navy. If the synergy of Creare and Sonomax produces a product or technology that can be commercialized, then it is agreed that both parties will work together to explore opportunities to jointly license the combined technology.
In the first study of its kind, New England Research Institutes, Inc. (NERI) in collaboration with the Division of Cardiology, San Francisco General Hospital and the University of California, San Francisco tested whether erectile dysfunction (ED) can be used to reclassify patients according to their future risk of developing cardiovascular disease (CVD) beyond traditional risk factors (such as smoking, high blood pressure, high cholesterol, etc).
Among breast cancer patients, both chemotherapy and tamoxifen independently reduced the risk of developing a second cancer in the other breast, according to a study published online December 25 in the Journal of the National Cancer Institute.
› Verified 2 days ago
| Entity Name | Aria Health Physician Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750949806 PECOS PAC ID: 3577467018 Enrollment ID: O20040224000045 |
News Archive
Axial Exchange, Inc., a pioneer in using mobile applications to deepen the patient's role in improving outcomes, launched a new Spanish-language version of its mobile application, making the company's innovative patient engagement tools available to a greater population.
Princeton University researchers have observed a self-degradation response to the antidepressant Zoloft in yeast cells that could help provide new answers to lingering questions among scientists about how antidepressants work, as well as support the idea that depression is not solely linked to the neurotransmitter serotonin.
Sonomax Technologies Inc. is pleased to announce that it has signed its first licensing deal whereby its groundbreaking V4 technology has been licensed to Creare Inc. (Creare) for use in a Research and Development (R&D) project being executed on behalf of the United States Navy. If the synergy of Creare and Sonomax produces a product or technology that can be commercialized, then it is agreed that both parties will work together to explore opportunities to jointly license the combined technology.
In the first study of its kind, New England Research Institutes, Inc. (NERI) in collaboration with the Division of Cardiology, San Francisco General Hospital and the University of California, San Francisco tested whether erectile dysfunction (ED) can be used to reclassify patients according to their future risk of developing cardiovascular disease (CVD) beyond traditional risk factors (such as smoking, high blood pressure, high cholesterol, etc).
Among breast cancer patients, both chemotherapy and tamoxifen independently reduced the risk of developing a second cancer in the other breast, according to a study published online December 25 in the Journal of the National Cancer Institute.
› Verified 2 days ago
| Entity Name | Hillmont G.i., P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952355984 PECOS PAC ID: 3375514144 Enrollment ID: O20040804001113 |
News Archive
Axial Exchange, Inc., a pioneer in using mobile applications to deepen the patient's role in improving outcomes, launched a new Spanish-language version of its mobile application, making the company's innovative patient engagement tools available to a greater population.
Princeton University researchers have observed a self-degradation response to the antidepressant Zoloft in yeast cells that could help provide new answers to lingering questions among scientists about how antidepressants work, as well as support the idea that depression is not solely linked to the neurotransmitter serotonin.
Sonomax Technologies Inc. is pleased to announce that it has signed its first licensing deal whereby its groundbreaking V4 technology has been licensed to Creare Inc. (Creare) for use in a Research and Development (R&D) project being executed on behalf of the United States Navy. If the synergy of Creare and Sonomax produces a product or technology that can be commercialized, then it is agreed that both parties will work together to explore opportunities to jointly license the combined technology.
In the first study of its kind, New England Research Institutes, Inc. (NERI) in collaboration with the Division of Cardiology, San Francisco General Hospital and the University of California, San Francisco tested whether erectile dysfunction (ED) can be used to reclassify patients according to their future risk of developing cardiovascular disease (CVD) beyond traditional risk factors (such as smoking, high blood pressure, high cholesterol, etc).
Among breast cancer patients, both chemotherapy and tamoxifen independently reduced the risk of developing a second cancer in the other breast, according to a study published online December 25 in the Journal of the National Cancer Institute.
› Verified 2 days ago
| Entity Name | Mt. Airy Anesthesiology Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437363512 PECOS PAC ID: 1557454295 Enrollment ID: O20070911000445 |
News Archive
Axial Exchange, Inc., a pioneer in using mobile applications to deepen the patient's role in improving outcomes, launched a new Spanish-language version of its mobile application, making the company's innovative patient engagement tools available to a greater population.
Princeton University researchers have observed a self-degradation response to the antidepressant Zoloft in yeast cells that could help provide new answers to lingering questions among scientists about how antidepressants work, as well as support the idea that depression is not solely linked to the neurotransmitter serotonin.
Sonomax Technologies Inc. is pleased to announce that it has signed its first licensing deal whereby its groundbreaking V4 technology has been licensed to Creare Inc. (Creare) for use in a Research and Development (R&D) project being executed on behalf of the United States Navy. If the synergy of Creare and Sonomax produces a product or technology that can be commercialized, then it is agreed that both parties will work together to explore opportunities to jointly license the combined technology.
In the first study of its kind, New England Research Institutes, Inc. (NERI) in collaboration with the Division of Cardiology, San Francisco General Hospital and the University of California, San Francisco tested whether erectile dysfunction (ED) can be used to reclassify patients according to their future risk of developing cardiovascular disease (CVD) beyond traditional risk factors (such as smoking, high blood pressure, high cholesterol, etc).
Among breast cancer patients, both chemotherapy and tamoxifen independently reduced the risk of developing a second cancer in the other breast, according to a study published online December 25 in the Journal of the National Cancer Institute.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Shawn Ulmen, CRNA 1740 Turk Rd, Doylestown, PA 18901-2811 Ph: (215) 230-4556 | Shawn Ulmen, CRNA 446 Bellevue Ave, Trenton, NJ 08618-4502 Ph: (609) 394-4221 |
News Archive
Axial Exchange, Inc., a pioneer in using mobile applications to deepen the patient's role in improving outcomes, launched a new Spanish-language version of its mobile application, making the company's innovative patient engagement tools available to a greater population.
Princeton University researchers have observed a self-degradation response to the antidepressant Zoloft in yeast cells that could help provide new answers to lingering questions among scientists about how antidepressants work, as well as support the idea that depression is not solely linked to the neurotransmitter serotonin.
Sonomax Technologies Inc. is pleased to announce that it has signed its first licensing deal whereby its groundbreaking V4 technology has been licensed to Creare Inc. (Creare) for use in a Research and Development (R&D) project being executed on behalf of the United States Navy. If the synergy of Creare and Sonomax produces a product or technology that can be commercialized, then it is agreed that both parties will work together to explore opportunities to jointly license the combined technology.
In the first study of its kind, New England Research Institutes, Inc. (NERI) in collaboration with the Division of Cardiology, San Francisco General Hospital and the University of California, San Francisco tested whether erectile dysfunction (ED) can be used to reclassify patients according to their future risk of developing cardiovascular disease (CVD) beyond traditional risk factors (such as smoking, high blood pressure, high cholesterol, etc).
Among breast cancer patients, both chemotherapy and tamoxifen independently reduced the risk of developing a second cancer in the other breast, according to a study published online December 25 in the Journal of the National Cancer Institute.
› Verified 2 days ago
Patricia Lauricella, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 416 Bellevue Ave, Ste 104, Trenton, NJ 08618 Phone: 609-396-4700 | |
Tamasina Phillips, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 416 Bellevue Ave, Suite 104, Trenton, NJ 08618 Phone: 800-394-4445 | |
Susan Macomber, C.R.N.A. Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 416 Bellevue Ave, Suite 104, Trenton, NJ 08618 Phone: 609-396-4700 Fax: 609-396-4900 | |
Mary Greenhalgh, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 416 Bellevue Ave, Ste 104, Trenton, NJ 08618 Phone: 609-396-4700 | |
Karen Groff, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 446 Bellevue Ave, Trenton, NJ 08618 Phone: 609-394-4221 Fax: 609-394-4681 | |
Gail Hughs, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 416 Bellevue Ave, Ste 104, Trenton, NJ 08618 Phone: 609-396-4700 Fax: 609-396-4900 | |
James M Campbell, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 416 Bellevue Ave, Suite 104, Trenton, NJ 08618 Phone: 609-396-4700 Fax: 609-396-4900 |